clinical trial · NCT06372496
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
GlaxoSmithKline·phase4·active not recruiting·n = 1,366
AsthmaFluticasone furoate/umeclidinium bromide/vilanterol trifenatateInhaled corticosteroids/long-acting beta-2 agonists
brief summary
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
started
Apr 16, 2024
primary completion
Jul 28, 2025
completion
Mar 31, 2027
last updated
Mar 24, 2026
official title
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol